Drug Search Results
More Filters [+]

Sapanisertib

Alternative Names: sapanisertib, mln0128, tak-228, tak 228, tak228, cb-228, cb228, cb 228
Latest Update: 2024-08-07
Latest Update Note: Clinical Trial Update

Product Description

Sapanisertib is a dual TORC 1/2 inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells. These mutations are found in a considerable sub-population of patients across multiple solid tumor types. (Sourced from: https://www.calithera.com/mtorc1-2-inhibitor-sapanisertib-cb-228/)

Mechanisms of Action: mTOR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Fast Track - Lung Cancer *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sapanisertib

Countries in Clinic: United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 2: Anaplastic Thyroid Carcinoma|Endometrial Cancer|Renal Cell Carcinoma|Thyroid Cancer|Transitional Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

FTH-PIK-201

P2

Not yet recruiting

Endometrial Cancer

2028-09-01

57%

FTH-PIK-201

P2

Not yet recruiting

Endometrial Cancer

2028-09-01

57%

NCT02244463

P2

Completed

Thyroid Cancer|Anaplastic Thyroid Carcinoma

2022-04-28

NCT03097328

P2

Completed

Renal Cell Carcinoma

2021-07-20

2017-004486-27

P2

Completed

Transitional Cell Carcinoma

2021-04-15

Recent News Events